Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues
- 1 February 2007
- journal article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 91 (2), 128-130
- https://doi.org/10.1136/bjo.2006.101337
Abstract
Intravitreal Avastin provides an opportunity to prevent visual acuity loss particularly in non‐Western countriesKeywords
This publication has 40 references indexed in Scilit:
- TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)Retina, 2006
- ELECTROPHYSIOLOGIC AND RETINAL PENETRATION STUDIES FOLLOWING INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN)Retina, 2006
- ELECTROPHYSIOLOGIC FINDINGS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENTRetina, 2006
- INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGERetina, 2006
- INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF MACULAR EDEMA IN CENTRAL RETINAL VEIN OCCLUSIONRetina, 2006
- REGRESSION OF RETINAL AND IRIS NEOVASCULARIZATION AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENTRetina, 2006
- Choroidal neovascularisation in pathological myopia: an update in managementBritish Journal of Ophthalmology, 2005
- Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia.2005
- Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Neovascular Age-Related Macular DegenerationOphthalmic Surgery, Lasers and Imaging Retina, 2005
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005